← Back to Search

Checkpoint Inhibitor

Nivolumab 360mg for Kidney Cancer

Phase 2
Waitlist Available
Research Sponsored by Michael B. Atkins, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new cancer drug in 120 patients who have not had any other treatment for their kidney cancer.

Eligible Conditions
  • Kidney Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Clinical Activity (Complete Response (CR), Partial Response (PR) and Stable Disease (SD)
Objective Response Rate (CR/PR)
Progression Free Survival (PFS) at one year
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: PART B: Nivolumab + IpilimumabExperimental Treatment3 Interventions
Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
Group II: PART A: NivolumabExperimental Treatment2 Interventions
Nivolumab 240mg; Nivolumab 360mg
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab 360mg
Completed Phase 2

Find a Location

Who is running the clinical trial?

Michael B. Atkins, MDLead Sponsor
1 Previous Clinical Trials
120 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,638 Previous Clinical Trials
4,128,350 Total Patients Enrolled
Hoosier Cancer Research NetworkOTHER
68 Previous Clinical Trials
3,591 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research still looking for participants?

"According to the website, this study is not presently looking for candidates as it has already completed recruitment. The original posting was on April 24th, 2017 with the most recent update being from October 25th, 2022. Although this trial is no longer active, there are 3461 other studies that are ongoing and actively recruiting patients."

Answered by AI

Are there other reports of Nivolumab's effects at 240 mg?

"Nivolumab, at a standard dosage of 240 mg, was first studied in 2009 Texas Children's Hospital. To date, there have been 360 completed clinical trials and presently there are 796 active ones; Chicago, Illinois has a large number of these ongoing studies."

Answered by AI

What condition has Nivolumab 240 mg been most successful in alleviating?

"Nivolumab 240mg can be used to treat patients that have undergone anti-angiogenic therapy, have malignant neoplasms, and/or unresectable melanoma."

Answered by AI

What are the dangers of Nivolumab 240 mg for patients who take it?

"Nivolumab 240 mg is considered to be a safe medication, as there is some clinical data supporting its safety. However, because this is only a Phase 2 trial, the efficacy of Nivolumab has not been conclusively determined."

Answered by AI

How many people can potentially enroll in this experiment?

"Unfortunately, this particular trial is no longer recruiting patients. It was initially posted on April 24th, 2017 and last edited on October 25th, 2022. However, there are presently 2665 trials actively searching for patients with carcinoma and 796 trials for Nivolumab 240 mg that are enrolling patients."

Answered by AI

Are there different sites where this research is taking place?

"There are 13 clinical trial sites for this study, which is recruiting patients. The locations include: Northwestern University Feinberg Schooll Of Medicine (Chicago, Illinois), University of Illinois Cancer Center (Washington, District of Columbia), Georgetown University (Atlanta, Georgia), and 10 other centres."

Answered by AI
~21 spots leftby Apr 2025